Lyell Immunopharma Stock Forecast

Stock Price Forecast

The 5 analysts that cover Lyell Immunopharma stock have a consensus rating of "Strong Buy" and an average price target of $30.6, which forecasts a 36.55% increase in the stock price over the next year. The lowest target is $10 and the highest is $45.

Price Target: $30.6 (+36.55%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$10	$30.6	$34	$45
Change	-55.38%	+36.55%	+51.72%	+100.80%

Analyst Ratings

The average analyst rating for Lyell Immunopharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Nov '25	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26
Strong Buy	1	2	2	2	2	3
Buy	0	0	0	0	1	1
Hold	2	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	3	3	3	3	4	5

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Gil Blum Needham	Needham	Strong Buy Initiates $44	Strong Buy	Initiates	$44	+96.34%	Apr 10, 2026
Reni J. Benjamin Citizens	Citizens	Buy Initiates $34	Buy	Initiates	$34	+51.72%	Mar 9, 2026
Mitchell S. Kapoor HC Wainwright & Co.	HC Wainwright & Co.	Hold → Strong Buy Upgrades $20 → $45	Hold → Strong Buy	Upgrades	$20 → $45	+100.80%	Dec 9, 2025
Mitchell S. Kapoor HC Wainwright & Co.	HC Wainwright & Co.	Hold Maintains $10 → $20	Hold	Maintains	$10 → $20	-10.75%	Nov 24, 2025
Christopher Liu LUCID CAPITAL MARKETS	LUCID CAPITAL MARKETS	Strong Buy Initiates $20	Strong Buy	Initiates	$20	-10.75%	Sep 26, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

17.54K

from 36.00K

-51.27%

from 36.00K

Revenue Next Year

1.55M

from 17.54K

8,712.13%

from 17.54K

EPS This Year

-9.90

from -16.06

EPS Next Year

-9.48

from -9.90

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	10.65M	84.68M	130.00K	61.00K	36.00K	17.54K	1.55M
Revenue Growth	37.31%	695.15%	-99.85%	-53.08%	-40.98%	-51.27%	8,712.13%
EPS	-36.82	-14.82	-18.70	-26.23	-16.06	-9.90	-9.48
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	7	6

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027
High	48,300	7.9M
Avg	17,544	1.5M
Low	n/a	n/a

Revenue Growth

Revenue Growth	2026	2027
High	34.2%	44,787.1%
Avg	-51.3%	8,712.1%
Low	-	-

EPS Forecast

EPS	2026	2027
High	-9.10	-8.64
Avg	-9.90	-9.48
Low	-11.04	-11.46

EPS Growth

EPS Growth	2026	2027
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.